Bristol Myers Squibb CELG-RI
NYSE CELG-RI
$0.12 +0.02 (+17.65%)
As of: Aug 21, 2026 · 2:40 PM EDT

Bristol Myers Squibb (CELG-RI) Goodwill & Intangibles (2009 - 2026)

Bristol Myers Squibb (CELG-RI) posted quarterly Goodwill & Intangibles of $39.1 billion for Q2 2026, down 9.33% year-over-year from $43.2 billion in Q2 2025, and down 2.14% quarter-over-quarter from $40.0 billion in Q1 2026.

Bristol Myers Squibb (CELG-RI) Goodwill & Intangibles (2009 - 2026) Analysis & Trends

Bristol Myers Squibb (CELG-RI) has reported Goodwill & Intangibles for 18 consecutive years, with $39.1 billion the latest figure, recorded in Q2 2026.

  • In Q2 2026, Goodwill & Intangibles fell 9.33% year-over-year to $39.1 billion; the TTM figure through Jun 2026 stood at $39.1 billion (down 9.33% YoY), while the FY2025 annual figure was $40.9 billion, down 9.26% from the prior year.
  • Goodwill & Intangibles eased to $39.1 billion in Q2 2026 per CELG-RI's latest filing, from $40.0 billion in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $60.6 billion in Q1 2022 and bottomed at $39.1 billion in Q2 2026.
  • Historically, Goodwill & Intangibles has averaged $49.4 billion across 5 years, with a median of $49.4 billion in 2023.
  • Annual changes were most pronounced in 2024 — Goodwill & Intangibles retreated 0.43% — and 2025, when it fell 18.85%.
  • Bristol Myers Squibb's Goodwill & Intangibles stood at $57.0 billion in 2022, then decreased by 15.38% to $48.2 billion in 2023, then dropped by 6.66% to $45.0 billion in 2024, then dropped by 9.26% to $40.9 billion in 2025, then fell by 4.23% to $39.1 billion in 2026.
  • Business Quant data shows CELG-RI's Goodwill & Intangibles at $39.1 billion in Q2 2026, $40.0 billion in Q1 2026, and $40.9 billion in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn
10 Bristol Myers Squibb 224.21 Mn -10.84 Bn 9.25 Bn

Historic Data

Download Data
DateValue
Jun 30, 2026 39.13 Bn
Mar 31, 2026 39.98 Bn
Dec 31, 2025 40.86 Bn
Sep 30, 2025 42.21 Bn
Jun 30, 2025 43.15 Bn
Mar 31, 2025 44.22 Bn
Dec 31, 2024 45.03 Bn
Sep 30, 2024 48.72 Bn
Jun 30, 2024 51.16 Bn
Mar 31, 2024 54.50 Bn
Dec 31, 2023 48.24 Bn
Sep 30, 2023 50.10 Bn
Jun 30, 2023 52.47 Bn
Mar 31, 2023 54.73 Bn
Dec 31, 2022 57.01 Bn
Sep 30, 2022 59.29 Bn
Jun 30, 2022 58.14 Bn
Mar 31, 2022 60.60 Bn
Dec 31, 2021 63.03 Bn
Sep 30, 2021 65.45 Bn